Credit Suisse Group set a $145.00 price objective on Incyte (NASDAQ:INCY) in a report released on Wednesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

INCY has been the topic of a number of other reports. JPMorgan Chase & Co. restated a buy rating on shares of Incyte in a report on Wednesday, October 25th. BidaskClub cut shares of Incyte from a sell rating to a strong sell rating in a report on Tuesday, January 16th. Cowen restated a buy rating on shares of Incyte in a report on Tuesday, December 5th. Royal Bank of Canada upgraded shares of Incyte from a sector perform rating to an outperform rating and set a $136.00 price target on the stock in a report on Tuesday, January 2nd. Finally, Deutsche Bank initiated coverage on shares of Incyte in a report on Tuesday, December 12th. They issued a hold rating and a $106.00 price target on the stock. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $142.94.

Incyte (NASDAQ INCY) opened at $88.17 on Wednesday. The company has a quick ratio of 4.81, a current ratio of 4.82 and a debt-to-equity ratio of 0.01. The company has a market cap of $18,577.61, a PE ratio of -110.21 and a beta of 0.59. Incyte has a 1-year low of $80.85 and a 1-year high of $153.15.

In other Incyte news, EVP Vijay K. Iyengar sold 5,000 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $97.26, for a total transaction of $486,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Reid M. Huber sold 696 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $98.01, for a total transaction of $68,214.96. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,456 shares of company stock valued at $1,222,876. Insiders own 17.70% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Financial Gravity Companies Inc. purchased a new stake in shares of Incyte during the fourth quarter valued at about $120,000. Private Advisor Group LLC purchased a new position in shares of Incyte in the 3rd quarter valued at approximately $203,000. Advantage Investment Management LLC raised its position in shares of Incyte by 1,233.3% in the 4th quarter. Advantage Investment Management LLC now owns 2,000 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 1,850 shares during the last quarter. Caxton Associates LP purchased a new position in shares of Incyte in the 3rd quarter valued at approximately $257,000. Finally, Mission Wealth Management LP purchased a new position in shares of Incyte in the 4th quarter valued at approximately $213,000. 90.02% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Incyte (INCY) Given a $145.00 Price Target by Credit Suisse Group Analysts” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2018/02/15/incyte-incy-given-a-145-00-price-target-by-credit-suisse-group-analysts.html.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.